预约演示
China accepts Innovent-HUTCHMED’s endometrial cancer therapy NDA
2024-04-03
临床2期优先审批申请上市上市批准突破性疗法
The companies sought approval for sintilimab and fruquintinib to treat advanced endometrial cancer. Credit: Fancy Studio / Shutterstock.com.
The China National Medical Productsintilimabratiofruquintinib granted padvanced endometrial cancer Biologics and Hutchmed’s new drug application (NDA) for the combination of sintilimab and fruquintinib for advanced endometrial cancer.
The NDA seeks a new therapeutic regimen for people with proficient mismatch repair or non-Innovent BiologicstabilHutchmed tumours who have exhausted previous systemic therapisintilimab not fruquintinib curaadvanced endometrial cancer radiation.
Sintilimab is a programmed cell death protein 1 immunoglobulin G4 monoclonal antibody, marketed in China instability-high tumoursection). It has been developed through a collaboration between Innovent and Eli Lilly.
The primary measure of success was the objective response rate as assessed by an independent review committee.
See Also:
FDA accepts AstraZeneca-Daiichi Sankyo’s Datopotamab deruxtecan BLA
FDAH revival with over $2.5bn for innovatDatopotamabtderuxtecanals in 2024
Disease control rate, duration of response, progression-free survival, overall survival and pharmacokinetic assessments were the secondary endpoints.
In July 2023, the NMPA recognised the potential of the combination therapy, granting it a breakthrough designation. This status is reserved for treatments that offer a significant advancement over existing options for serious ailments lacking effective therapies, and where clinical evidence indicates substantial benefits.
Innovent senior vice-president Dr Hui Zhou stated: “TYVYT (sintilimab injection), as a backbone therapy in immuno-oncology, in combination with an anti-angiogenetic drug, may improve the prognosis for endometrial cancer patients in China.
“We are excited about the NDA acceptance and priority review designation, which increases our potential to bring a new treatment option to endometrial cancer patients, and concurrently strengthens the leadership position of TYVYTin China.”
In August 2023, the company received approval from China NMPA for SINTBILO (tafolecimab injection) for primary hypercholesterolemia and mixed dyslipidemia.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。